Clinical Trial: Magnesium Sulphate for Neonatal Asphyxia and Length of Hospital Stay

U.S., Sept. 24 -- ClinicalTrials.gov registry received information related to the study (NCT07835529) titled 'Magnesium Sulphate for Neonatal Asphyxia and Length of Hospital Stay' on Sept. 14.

Brief Summary: Neonatal asphyxia causes significant global morbidity, frequently resulting in Hypoxic-Ischemic Encephalopathy (HIE). In resource-limited settings where therapeutic hypothermia is unavailable, affordable neuroprotective options are needed. Intravenous magnesium sulphate blocks NMDA receptors, limiting cellular calcium influx and neuroinflammation. This randomized controlled trial evaluates whether adjuvant intravenous magnesium sulphate (250\text{ mg/kg} within 6 hours of birth) reduces the duration of hospital stay and improves short-...